Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne - 13/01/18
Abstract |
Scientific advances are continually improving the knowledge of acne and contributing to the refinement of treatment options; it is important for clinicians to regularly update their practice patterns to reflect current standards. The Global Alliance to Improve Outcomes in Acne is an international group of dermatologists with an interest in acne research and education that has been meeting regularly since 2001. As a group, we have continuously evaluated the literature on acne. This supplement focuses on providing relevant clinical guidance to health care practitioners managing patients with acne, with an emphasis on areas where the evidence base may be sparse or need interpretation for daily practice.
Le texte complet de cet article est disponible en PDF.Key words : acne vulgaris, adult acne, scar, post-inflammatory hyperpigmentation
Abbreviations used : AAD, A/BPO, EDF, FASET, FDA, IGA, OC, OG, PIH
Plan
Publication of this article was supported by an unrestricted educational grant provided by Galderma International SAS, Paris, France. |
|
Conflicts of interest: All authors have served as advisory board members for Galderma and received honoraria. In addition, Dr Thiboutot has received fees and research funding for serving as a consultant and investigator for Allergan, Mimetica, Novan, and Sebacia and as a consultant for Dermira, Galderma, Photosonix, and Xenon. Dr Dreno has received honoraria serving as an advisory board member for Meda. Dr Alexis has received consulting fees from Roche, honoraria serving as an advisory board member for Allergan and Foamix and received grants paid to his institution for serving as an investigator for BioPharmix, Allergan, and Novan. Dr Araviiskaia has served as an advisory board member for L'Oreal and Vicy and received honoraria for speaking for La Roche Posay, Astellas Pharma, Pierre Fabre, Uriage, Jadran JGL, Glenmark, Meda, and Bayer Healthcare. Dr Costa has received honoraria and grants serving as an advisory board member for Hypermarcas, L'Oreal, and Avon and as an investigator for Galderma and Hypermarcas. Dr Hayashi received fees and honoraria serving as a speaker and consultant for Maruho and Glaxo SmithKline and as a speaker for Pola Pharma. Dr Herane has received honoraria serving as an advisory board member for Galderma. Dr Layton has received grants, fees, research funding, and honoraria for serving as an advisory board member, speaker, and investigator for Galderma, a consultant for Glaxo SmithKline, and an investigator and speaker for Meda. Dr Leyden has received honoraria serving as an advisory board member for Allergan and a consultant for BioPharmX, Unliver, Cutanea, and Foamix. Dr See has received honoraria serving as an advisory board member for Allergan and Meda. Dr Tan has received honoraria and grants serving as an advisory board member for Allergan, Bayer, Cipher, Valeant, and Roche; a speaker for Cipher, Valeant, and Pierre Fabre; an investigator for Dermira, Galderma, and Xenon; and a consultant for Galderma, Xenon, and Boots/Walgreens. Dr Torres has received honoraria servinh as an advisory board member for Galderma. Dr Troielli has received honoraria serving as a speaker for La Roche Posay and a speaker and investigator for Galderma. |
Vol 78 - N° 2S1
P. S1-S23.e1 - février 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?